Type b (Hib) Conjugate Vaccine Haemophilus influenzae Precautions and Contraindications Screen all patients for precautions and contraindications to immunizations. Vaccine Information Statements Provide all patients with a copy of the most current federal Vaccine Information Statement (VIS). Provide a non-English speaking patient with a copy of the VIS in native language, if one is available and desired; these VISs can be found at . FDA Approved Indications and Usage (See Package Insert for ActHIB®, current version dated 12/2015 ActHIB is a vaccine indicated for the prevention of invasive disease caused by type b. ActHIB vaccine is approved for use as a four-dose series Haemophilus influenza in infants and children 2 months through 5 years of age. FDA Approved Indications and Usage (See Package Insert for PedvaxHIB®, current version dated 12/2010 PedvaxHIB is indicated for routine vaccination against invasive disease caused by type b in infants and children 2 to 71 months of age. Haemophilus influenza Recommended Schedule ActHIB (PRP-T) Hib Vaccine Schedule for Unimmunized Children Without Any Previous Doses Age Receiving 1st Dose Dose Recommended Age Accelerated Schedule 11 2 months > 6 weeks of age 21 4 months > 1 month after dose #1 0 6 months – 31 6 months > 1 month after dose #2 > 2 months after previous dose and 4 12 through 15 months > 12 months of age 11 - 1st visit 21 - > 1 month after dose #1 7 11 months – > 2 months after previous dose and 31 - between 12 through 15 months of age 12 - 1st visit 12 14 months – 22 - > 2 months after previous dose 15 59 months 1 - 1st visit – 1 When feasible, use same vaccine for 1 3. – 2 When feasible, use same vaccine for doses 1 2. –
Haemophilus influenzae Type b (Hib) Conjugate Vaccine Precautions and Contraindications Screen all patients for precautions and contraindications to immunizations. Vaccine Information Statements Provide all patients with a copy of the most current federal Vaccine Information Statement (VIS). Provide a non-English speaking patient with a copy of the VIS in native language, if one is available and desired; these VISs can be found at . FDA Approved Indications and Usage (See Package Insert for ActHIB®, current version dated 12/2015 ActHIB is a vaccine indicated for the prevention of invasive disease caused by Haemophilus influenza type b. ActHIB vaccine is approved for use as a four-dose series in infants and children 2 months through 5 years of age. FDA Approved Indications and Usage (See Package Insert for PedvaxHIB®, current version dated 12/2010 PedvaxHIB is indicated for routine vaccination against invasive disease caused by Haemophilus influenza type b in infants and children 2 to 71 months of age. Recommended Schedule ActHIB (PRP-T) Hib Vaccine Schedule for Unimmunized Children Without Any Previous Doses Age Receiving 1st Dose Dose Recommended Age Accelerated Schedule 0 – 6 months 11 2 months > 6 weeks of age 21 4 months > 1 month after dose #1 31 6 months > 1 month after dose #2 4 12 through 15 months > 2 months after previous dose and > 12 months of age 7 – 11 months 11 - 1st visit 21 - > 1 month after dose #1 31 - > 2 months after previous dose and between 12 through 15 months of age 12 – 14 months 12 - 1st visit 22 - > 2 months after previous dose 15 – 59 months 1 - 1st visit 1 When feasible, use same vaccine for 1 – 3. 2 When feasible, use same vaccine for doses 1 – 2.